Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation
Novel cancer immunotherapy is being assessed in nationwide SURVIVE trial in adults with glioblastoma, and in studies for other applications in children and adults. The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 14, 2023 Category: Pharmaceuticals Tags: TRI FDA Source Type: news
Ocean Biomedical partners to bring hepatitis B drug to human trials
The goal of the new joint venture is to develop treatments for cancer and infectious diseases using T cell-based immunotherapies. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 12, 2023 Category: Pharmaceuticals Authors: Mary Serreze Source Type: news
ESMO 2023: A Wealth of New Data Across Cancer Types ESMO 2023: A Wealth of New Data Across Cancer Types
The march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Sublingual Immunotherapy May Result in Desensitization and Remission for Peanut-Allergic Children
60% of peanut-allergic children in the test group experience desensitization to peanut protein after sublingual immunotherapy according to research from JACI, an official journal of the AAAAI. MILWAUKEE, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Peanut sublingual immunotherapy (SLIT) is safe... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 10, 2023 Category: Pharmaceuticals Tags: TRI SVY Source Type: news
Mayo Clinic prepares to biomanufacture a new CAR-T cell therapy for recurring B-cell blood cancers
This study… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 10, 2023 Category: Databases & Libraries Source Type: news
The Society for Immunotherapy of Cancer and the International Bladder Cancer Group Publish Recommendations for Clinical Trial Design in Bladder Cancer
The Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG) are pleased to announce the publication of the "Definitions, End Points, and Clinical Trial Designs in Bladder Cancer: Recommendations from the Society for Immunotherapy of Cancer and the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
SITC's Goal: Attract San Diego Students to Careers in STEM
The Society for Immunotherapy of Cancer (SITC) is pleased to introduce young San Diego minds to a career in science and medicine. SITC, the only member-driven society dedicated to the research and application of cancer immunotherapy, is holding a free, day-long program for college... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 5, 2023 Category: Pharmaceuticals Tags: FVT Source Type: news
Immunotherapy Combinations for Metastatic Prostate Cancer Immunotherapy Combinations for Metastatic Prostate Cancer
Despite multiple trials, finding effective combination immunotherapy treatments for metastatic castration resistant prostate cancer remains elusive. What ' s next on the horizon?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 3, 2023 Category: Consumer Health News Tags: Urology Journal Article Source Type: news
Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer
(MedPage Today) -- Combination treatment with an investigational anti-TIGIT drug plus a PD-L1 inhibitor was well tolerated and demonstrated promising activity in patients with metastatic non-small cell lung cancer (NSCLC) and esophageal cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2023 Category: Hematology Source Type: news
Study provides new look at why rare cancer often evades treatments
Researchers at Boston Medical Center and Dana-Farber Cancer Institute conducted one of the first-ever analyses of neuroendocrine tumors (NETs) at single cell resolution, unlocking new insights into this rare and often hard-to-treat cancer. The findings represent a tremendous leap forward in understanding why these tumors are largely resistant to immunotherapy and provide key insights that could lead to future treatments. (Source: World Pharma News)
Source: World Pharma News - September 27, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Combo Immunotherapy With Durvalumab Effective for NSCLC
MONDAY, Sept. 25, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), combination immunotherapy with the anti-programmed death-ligand 1 monoclonal antibody durvalumab and other novel agents outperforms durvalumab alone in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2023 Category: Pharmaceuticals Source Type: news
New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
A combination immunotherapy developed by biotech company Agenus administered before surgery destroyed over 80% of a tumor before it was removed. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 21, 2023 Category: Pharmaceuticals Authors: Alex Knapp, Forbes Staff Tags: Science /science Innovation /innovation Healthcare /healthcare Editors' Pick editors-pick technology alexknappblog premium Source Type: news
Therapeutic Vaccine Shows Promise in Treating Lung Cancer Therapeutic Vaccine Shows Promise in Treating Lung Cancer
In a study that did not achieve its recruitment goal, the patients who benefited most from the vaccine had previously responded to immunotherapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
How to Speed Up Cell Therapy Development Processes
In this webinar, Patrick Schmidt will explore how to streamline CAR T cell product manufacturing processes for immunotherapy. (Source: The Scientist)
Source: The Scientist - September 15, 2023 Category: Science Tags: Sponsored Webinars Source Type: news
Should NSCLC Patients Receive Immunotherapy'Indefinitely'? Should NSCLC Patients Receive Immunotherapy'Indefinitely'?
Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
